SLC16A1 and atherosclerosis: Inhibiting MCT1 reduces lactate‐induced vascular inflammation and atherosclerosis in Apoe−/− mice, suggesting that the lactate‐dependent NADH/CtBP/FOXP1 pathway is a potential therapeutic target.